Solid Biosciences Inc. (NASDAQ:SLDB) Sees Large Decline in Short Interest

Solid Biosciences Inc. (NASDAQ:SLDB) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 8,602,169 shares, a decrease of 14.2% from the December 31st total of 10,029,089 shares. Based on an average daily volume of 1,147,561 shares, the short-interest ratio is presently 7.5 days. Currently, 12.8% of the shares of the company are sold short. Currently, 12.8% of the shares of the company are sold short. Based on an average daily volume of 1,147,561 shares, the short-interest ratio is presently 7.5 days.

Insider Buying and Selling at Solid Biosciences

In other Solid Biosciences news, insider Gabriel Brooks sold 28,335 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $182,477.40. Following the sale, the insider directly owned 96,708 shares in the company, valued at $622,799.52. The trade was a 22.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin Tan sold 26,837 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $172,830.28. Following the transaction, the chief financial officer directly owned 108,984 shares in the company, valued at $701,856.96. This represents a 19.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 455,007 shares of company stock valued at $2,892,048 in the last quarter. Insiders own 13.63% of the company’s stock.

Institutional Investors Weigh In On Solid Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of SLDB. AQR Capital Management LLC bought a new stake in Solid Biosciences during the first quarter valued at approximately $418,000. Goldman Sachs Group Inc. raised its position in shares of Solid Biosciences by 32.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company’s stock valued at $667,000 after buying an additional 43,910 shares in the last quarter. Woodline Partners LP bought a new stake in shares of Solid Biosciences during the 1st quarter worth $2,338,000. Blair William & Co. IL bought a new stake in shares of Solid Biosciences during the 2nd quarter worth $807,000. Finally, ProShare Advisors LLC purchased a new position in Solid Biosciences in the second quarter worth $80,000. 81.46% of the stock is owned by hedge funds and other institutional investors.

Solid Biosciences Trading Up 2.0%

Shares of Solid Biosciences stock traded up $0.13 during trading on Tuesday, hitting $6.56. The stock had a trading volume of 220,728 shares, compared to its average volume of 1,005,595. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $7.37. The firm has a market cap of $511.09 million, a price-to-earnings ratio of -2.62 and a beta of 2.67. The business’s 50-day moving average is $5.75 and its 200 day moving average is $5.71.

Solid Biosciences (NASDAQ:SLDB) last posted its earnings results on Monday, November 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.06). As a group, equities analysts expect that Solid Biosciences will post -2.84 EPS for the current year.

Analysts Set New Price Targets

SLDB has been the subject of several recent research reports. Wall Street Zen downgraded shares of Solid Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, October 19th. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a report on Wednesday, January 14th. Chardan Capital restated a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a research report on Tuesday, November 4th. Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.70.

Trending Headlines about Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Analyst backdrop remains constructive — the stock carries a consensus “Moderate Buy” with a materially higher average price target (~$14.70), which supports longer?term demand and helps explain buying interest.
• Neutral Sentiment: Technical & ownership context is mixed — volume is modestly above average, the share price sits inside its 52?week range ($2.41–$7.37) and the 50/200?day moving averages are roughly $5.75/$5.71. Institutional ownership is high (~81%), which can both stabilize shares and limit volatility. Market Data
• Negative Sentiment: Coordinated insider selling is the main near?term negative — multiple senior executives (CEO Alexander Cumbo, COO David Howton, CTO Paul Herzich, CFO Kevin Tan, plus other insiders) disclosed sales on Feb. 2 at an average price of $6.44. Disclosed sales total roughly 226k shares (?$1.45M), with individual position trims in the ~20–25% range; that can weigh on sentiment and cap upside until the market digests the reasoning behind the disposals. Representative filings and writeups: InsiderTrades Article CEO SEC Filing

About Solid Biosciences

Solid Biosciences Inc is a clinical?stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle?stabilizing protein.

Solid’s lead investigational therapy, SGT?001, is a micro?dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno?associated virus (AAV) vector.